Jul 15, 2022 / 12:00PM GMT
Operator
Good day, and welcome to the Camurus Q2 2022 Earnings Conference Call. (Operator Instructions) Please note, this event is being recorded.
I would now like to turn the conference over to Fredrik Tiberg. Please go ahead.
Fredrik Tiberg - Camurus AB(publ)-CEO - President & Director
Thank you so much, and hello, everybody. Thank you for taking the time to joining us this Friday afternoon for our second quarter earnings call. It's a pleasure to update you on the continued progress of Camurus.
Please note our forward-looking statements. And this is today's agenda. With me on the call is Jon Garay, our Chief Financial Officer; and on the phone from Cambridge, U.K., is Richard Jameson, our Chief Commercial Officer.
Before going to highlights, here is a snapshot of Camurus 3 years after the approval and launch of our first transformative medicine, Buvidal. We have gone far proven our commercial execution ability and emerged as a leader in the opioid dependence treatment field, advanced our late
Q2 2022 Camurus AB Earnings Call Transcript
Jul 15, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers